| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 1,000 | 0 |
| Sales Growth | unch | unch | -100.00% | unch | unch |
| Net Income | -88,850 | -90,210 | -60,350 | -50,160 | -40,050 |
| Net Income Growth | +1.51% | -49.48% | -20.32% | -25.24% | +41.63% |
Terns Pharmaceuticals Inc
(TERN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY, Calif.
Fiscal Year End Date: 12/31